Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 14/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 3/20 | 0.33 |
| ▸ | CASP6 | P55212 | 2/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7254765 | 0.74 | CASP3 (0.38) | CASP1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1409148 | 0.71 | ALDH1A1 (0.35) | CASP1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2217364 | 0.71 | ALDH1A1 (0.35) | CASP1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL645654 | 0.71 | CASP1 (0.48) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL644624 | 0.71 | CASP1 (0.48) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL311041 | 0.70 | KLK5 (0.36) | CASP1ALDH1A1HPGD | |
| SCHEMBL8764759 | 0.69 | CASP1 (0.47) | CASP1CASP3 | |
| SCHEMBL646188 | 0.69 | CASP1 (0.44) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL4439353 | 0.68 | CYP3A4 (0.58) | ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL8764753 | 0.68 | CASP1 (0.43) | CASP1ALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | CASP1 5/4885ALDH1A1 458/4885HPGD 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.